{"id":380162,"date":"2020-11-12T15:53:38","date_gmt":"2020-11-12T20:53:38","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380162"},"modified":"2020-11-12T15:53:38","modified_gmt":"2020-11-12T20:53:38","slug":"shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/","title":{"rendered":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Odonate Therapeutics, Inc.\u2013 ODT; IMPORTANT NOV. 16 DEADLINE- ODT"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Nov.  12, 2020  (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) from December 7, 2017 through August 21, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Odonate Therapeutics, Inc. investors under the federal securities laws.<\/p>\n<p>To join the class action, go <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4dubICYbBDr__McIVKInSo6ls2RhULfeI6gBXD3o4Oe2aTMYGDtkKepnPlfFRwvzaQesvGdQXCemU2xSSqsgYJzUum7GQldryprNifk_kJOImtQGB4C7ZQIcwK9lqVvwEauZ4n3k6YOyrhnYraJCWw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a> or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ufwfRZhP3IoT97wWxbpnp611snYzdHeB9GhcyGJ19Kf38U8kd2zEseiNfX3hKppE9l_9mmJ6BVmuL0YR0ENV9Zr6G-djcZmshmry0sE9KCE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@pawarlawgroup.com<\/a>\u00a0for information on the class action.<\/p>\n<p>According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (1) tesetaxel was not as safe or well-tolerated as the Company had led investors to believe; (2) consequently, tesetaxel\u2019s commercial viability as a cancer treatment was overstated; and (3) as a result, the Company\u2019s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n<p>If you wish to serve as lead plaintiff, you must move the Court no later than <strong>November <\/strong><strong>1<\/strong><strong>6<\/strong><strong>, 2020<\/strong>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n<p>No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.<\/p>\n<p>Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.<br \/>&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;-<\/p>\n<p>Contact:\u00a0\u00a0<br \/>Vik Pawar, Esq.\u00a0\u00a0<br \/>Pawar Law Group\u00a0\u00a0<br \/>20 Vesey Street, Suite 1410\u00a0\u00a0<br \/>New York, NY 10007\u00a0\u00a0<br \/>Tel: (917) 261-2277\u00a0\u00a0<br \/>Fax: (212) 571-0938\u00a0\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ufwfRZhP3IoT97wWxbpnp611snYzdHeB9GhcyGJ19KcaQQHwy2Q8LDkKn7Q5EAimZQbNGN9TnQYO1OHaTYI9JX_gkGEGe5fgKdFmt7CLbyU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@pawarlawgroup.com<\/a>\u00a0\u00a0<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMxMyMzODI1MTM3IzIwODMxNDk=\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) from December 7, 2017 through August 21, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Odonate Therapeutics, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (1) tesetaxel was not as safe or well-tolerated as the Company had led investors to believe; (2) consequently, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Odonate Therapeutics, Inc.\u2013 ODT; IMPORTANT NOV. 16 DEADLINE- ODT&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380162","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Odonate Therapeutics, Inc.\u2013 ODT; IMPORTANT NOV. 16 DEADLINE- ODT - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Odonate Therapeutics, Inc.\u2013 ODT; IMPORTANT NOV. 16 DEADLINE- ODT - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) from December 7, 2017 through August 21, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Odonate Therapeutics, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (1) tesetaxel was not as safe or well-tolerated as the Company had led investors to believe; (2) consequently, &hellip; Continue reading &quot;SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Odonate Therapeutics, Inc.\u2013 ODT; IMPORTANT NOV. 16 DEADLINE- ODT&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-12T20:53:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMxMyMzODI1MTM3IzIwODMxNDk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Odonate Therapeutics, Inc.\u2013 ODT; IMPORTANT NOV. 16 DEADLINE- ODT\",\"datePublished\":\"2020-11-12T20:53:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\\\/\"},\"wordCount\":323,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTMxMyMzODI1MTM3IzIwODMxNDk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\\\/\",\"name\":\"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Odonate Therapeutics, Inc.\u2013 ODT; IMPORTANT NOV. 16 DEADLINE- ODT - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTMxMyMzODI1MTM3IzIwODMxNDk=\",\"datePublished\":\"2020-11-12T20:53:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTMxMyMzODI1MTM3IzIwODMxNDk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTMxMyMzODI1MTM3IzIwODMxNDk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Odonate Therapeutics, Inc.\u2013 ODT; IMPORTANT NOV. 16 DEADLINE- ODT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Odonate Therapeutics, Inc.\u2013 ODT; IMPORTANT NOV. 16 DEADLINE- ODT - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Odonate Therapeutics, Inc.\u2013 ODT; IMPORTANT NOV. 16 DEADLINE- ODT - Market Newsdesk","og_description":"NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) from December 7, 2017 through August 21, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Odonate Therapeutics, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose that: (1) tesetaxel was not as safe or well-tolerated as the Company had led investors to believe; (2) consequently, &hellip; Continue reading \"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Odonate Therapeutics, Inc.\u2013 ODT; IMPORTANT NOV. 16 DEADLINE- ODT\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-12T20:53:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMxMyMzODI1MTM3IzIwODMxNDk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Odonate Therapeutics, Inc.\u2013 ODT; IMPORTANT NOV. 16 DEADLINE- ODT","datePublished":"2020-11-12T20:53:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/"},"wordCount":323,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMxMyMzODI1MTM3IzIwODMxNDk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/","name":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Odonate Therapeutics, Inc.\u2013 ODT; IMPORTANT NOV. 16 DEADLINE- ODT - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMxMyMzODI1MTM3IzIwODMxNDk=","datePublished":"2020-11-12T20:53:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMxMyMzODI1MTM3IzIwODMxNDk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMxMyMzODI1MTM3IzIwODMxNDk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-odonate-therapeutics-inc-odt-important-nov-16-deadline-odt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Odonate Therapeutics, Inc.\u2013 ODT; IMPORTANT NOV. 16 DEADLINE- ODT"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380162","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380162"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380162\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380162"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380162"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380162"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}